SUTRO BIOPHARMA, INC. — Director's Dealing 2021

Sep 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: SUTRO BIOPHARMA, INC. (STRO)
CIK: 0001382101
Period of Report: 2021-09-24

Reporting Person: Vasquez Nicki (Chief Port. Strat & Alnce Ofcr)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-09-24	Common Stock	M	5969	$0.00	Acquired	13239	Direct
2021-09-24	Common Stock	F	2063	$19.23	Disposed	11176	Direct
2021-09-28	Common Stock	S	3906	$18.6186	Disposed	7270	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-09-24	Restricted Stock Unit (RSU)	$	M	5969	Disposed	2021-09-26	Common Stock (5969)	Direct

Footnotes

F1: Represents the number of shares of Common Stock that have been withheld by the issuer to satisfy its income tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent a sale by the reporting person.

F2: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.47 to $19.08 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F4: Each RSU represents a contingent right to receive one (1) share of the issuer's Common Stock upon settlement.

F5: The RSUs vest as to 1/3rd of the total shares annually beginning on September 26, 2019, subject to continued service through each vesting date.